SpringerLink
Log in

An Old Bridge to the Newer Biologics: Cyclosporine for Rescue Therapy in Acute Severe Ulcerative Colitis

  • Multicenter Seminars: IBD (MUSE: IBD)
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Loftus CG, Egan LJ, Sandborn WJ. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin N Am 2004;33:vii.

    Google Scholar 

  2. Rubin DT, Ananthakrishnan AN, Siegel CA et al. ACG Clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019;114:384–413.

    Article  PubMed  Google Scholar 

  3. Barberio B, Black CJ, Savarino EV, Ford AC. Ciclosporin or infliximab as rescue therapy in acute glucorticosteroid-refractory ulcerative colitis: systematic review and network meta-analysis. J Crohns Colitis 2021;15:733–741.

    Article  PubMed  Google Scholar 

  4. Szántó K, Molnár T, Farkas K. New promising combo therapy in inflammatory bowel diseases refractory to anti-TNF agents: cyclosporine plus vedolizumab. J Crohns Colitis 2018;12:629.

    Article  PubMed  Google Scholar 

  5. Christensen B, Gibson PR, Micic D et al. Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease. Clin Gastroenterol Hepatol 2019;17:486–493.

    Article  CAS  PubMed  Google Scholar 

  6. Pellet G, Stefanescu C, Carbonnel F et al. Efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab in patients with refractory ulcerative colitis. Clin Gastroenterol Hepatol 2019;17:494–501.

    Article  CAS  PubMed  Google Scholar 

  7. Ollech JE, Dwadasi S, Rai V et al. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2020;51:637–643.

    Article  CAS  PubMed  Google Scholar 

  8. Resál T, Pigniczki D, Szántó K et al. Letter: ciclosporin and vedolizumab for steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2020;52:578–579.

    Article  PubMed  Google Scholar 

  9. Ganzleben I, Geppert C, Osaba L et al. Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis. Therap Adv Gastroenterol 2020;13:1756284820954112.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Shaffer SR, Traboulsi C, Krugliak Cleveland N, Rubin DT. Combining cyclosporine with ustekinumab in acute severe ulcerative colitis. ACG Case Rep J 2021;8:e00604.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Lichtenstein GR, Loftus EV, Isaacs KL et al. ACG Clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 2018;113:481–517.

    Article  PubMed  Google Scholar 

  12. Feagan BG, Lasch K, Lissoos T et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2019;17:130-138.e137.

    Article  CAS  PubMed  Google Scholar 

  13. Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA technical review on the management of moderate to severe ulcerative colitis. Gastroenterology 2020;158:1465-1496.e1417.

    Article  CAS  PubMed  Google Scholar 

  14. Click B, Regueiro M. A practical guide to the safety and monitoring of new IBD therapies. Inflamm Bowel Dis 2019;25:831–842.

    Article  PubMed  Google Scholar 

  15. Weisshof R, Ollech JE, El Jurdi K et al. Ciclosporin therapy after infliximab failure in hospitalized patients with acute severe colitis is effective and safe. J Crohns Colitis 2019;13:1105–1110.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research was supported by grants from the National Institutes of Health [K23DK127157-01 ELB].

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Campus Box #7080, 130 Mason Farm Road, Chapel Hill, NC, 27599-7080, USA

    Divya Ashat, Animesh Jain, Kimberly N. Weaver, Millie D. Long, Hans H. Herfarth & Edward L. Barnes

  2. Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Divya Ashat, Animesh Jain, Kimberly N. Weaver, Millie D. Long, Hans H. Herfarth & Edward L. Barnes

Authors
  1. Divya Ashat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Animesh Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kimberly N. Weaver
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Millie D. Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hans H. Herfarth
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Edward L. Barnes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward L. Barnes.

Ethics declarations

Conflict of interest

Hans H. Herfarth has served as a consultant for Alivio, AMAG, BMS, ExeGI, Finch, Janssen, Gilead, Lycera, Merck, Otsuka, Pfizer, PureTech, Seres and research support from Pfizer and Artizan Biosciences. Millie D. Long has served as a consultant for AbbVie, UCB, Takeda, Janssen, Pfizer, Salix, Valeant, Target Pharmasolutions and has received research support from Pfizer and Takeda. Kimberly N. Weaver has served as a consultant for AbbVie. Edward L. Barnes has served as a consultant for AbbVie, Pfizer, and Target RWE. Divya Ashat and Animesh Jain have no relevant disclosures for this work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ashat, D., Jain, A., Weaver, K.N. et al. An Old Bridge to the Newer Biologics: Cyclosporine for Rescue Therapy in Acute Severe Ulcerative Colitis. Dig Dis Sci 67, 5439–5443 (2022). https://doi.org/10.1007/s10620-022-07682-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-022-07682-7

Keywords

Search

Navigation